Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
With appropriate formulation strategies, including the use of absorption enhancers and protective carriers, intranasal GLP-1 therapies could offer a noninvasive, patient-friendly alternative to injections
Hypoglycaemia can occur with GLP-1 agonists, especially if used alongside sulfonylureas or insulin.3 Diabetics on GLP-1 Agonists can also present with episodes of hyperglycaemia and DKA.3 In such cases, it is important to look beyond the acute management and consider whether problems with regular access to medication is a contributing factor
ArticlePubMed 154
(2013) 8:e66418
US$ 21.20
US$ 20.98
US$ 27.44
US$ 21.80
US$ 22.13
US$ 24.25
US$ 23.08
US$ 23.56
US$ 27.00
US$ 21.79
US$ 25.41
